The stock of Theravance Biopharma Inc (NASDAQ:TBPH) is a huge mover today! About 302,968 shares traded hands or 4.74% up from the average. Theravance Biopharma Inc (NASDAQ:TBPH) has risen 75.47% since March 15, 2016 and is uptrending. It has outperformed by 69.99% the S&P500.
The move comes after 6 months positive chart setup for the $1.50 billion company. It was reported on Oct, 18 by Barchart.com. We have $42.19 PT which if reached, will make NASDAQ:TBPH worth $570.00M more.
Analysts await Theravance Biopharma Inc (NASDAQ:TBPH) to report earnings on November, 14. They expect $-0.97 earnings per share, up 30.71% or $0.43 from last year’s $-1.4 per share. After $-1.06 actual earnings per share reported by Theravance Biopharma Inc for the previous quarter, Wall Street now forecasts -8.49% EPS growth.
Theravance Biopharma Inc (NASDAQ:TBPH) Ratings Coverage
Out of 4 analysts covering Theravance Biopharma (NASDAQ:TBPH), 3 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 75% are positive. Theravance Biopharma has been the topic of 5 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The company was maintained on Wednesday, August 12 by Robert W. Baird. Robert W. Baird downgraded the stock to “Underperform” rating in Wednesday, October 12 report. Guggenheim initiated Theravance Biopharma Inc (NASDAQ:TBPH) on Monday, June 20 with “Buy” rating. Leerink Swann initiated Theravance Biopharma Inc (NASDAQ:TBPH) on Thursday, May 12 with “Outperform” rating. The firm has “Buy” rating given on Monday, August 29 by Evercore.
According to Zacks Investment Research, “Theravance Biopharma, Inc. is a biopharmaceutical company. It is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including bacterial infections, central nervous system (CNS)/pain, respiratory disease, and gastrointestinal (GI) motility dysfunction. Theravance Biopharma, Inc. is based in George Town, Cayman Islands.”
Insitutional Activity: The institutional sentiment increased to 3.32 in 2016 Q2. Its up 1.98, from 1.34 in 2016Q1. The ratio is positive, as 5 funds sold all Theravance Biopharma Inc shares owned while 14 reduced positions. 22 funds bought stakes while 41 increased positions. They now own 48.58 million shares or 135.18% more from 20.66 million shares in 2016Q1.
Moreover, Royal Fincl Bank Of Canada has 0% invested in Theravance Biopharma Inc (NASDAQ:TBPH) for 10,210 shares. Moreover, Blackrock has 0% invested in Theravance Biopharma Inc (NASDAQ:TBPH) for 3,821 shares. Moreover, Barclays Public Ltd Company has 0% invested in Theravance Biopharma Inc (NASDAQ:TBPH) for 13,489 shares. Sei Invests has 2 shares for 0% of their US portfolio. The Florida-based Ladenburg Thalmann Financial Services Inc has invested 0% in Theravance Biopharma Inc (NASDAQ:TBPH). Cormorant Asset Management Limited Company last reported 1.12 million shares in the company. Moreover, Tower Rech Limited Liability Corp (Trc) has 0% invested in Theravance Biopharma Inc (NASDAQ:TBPH) for 229 shares. The United Kingdom-based Blackrock Gru Limited has invested 0% in Theravance Biopharma Inc (NASDAQ:TBPH). Marshall Wace Ltd Liability Partnership holds 0% or 23,706 shares in its portfolio. Moreover, Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Theravance Biopharma Inc (NASDAQ:TBPH) for 2,372 shares. Wells Fargo & Mn reported 12,331 shares or 0% of all its holdings. State Of New Jersey Common Pension Fund D has 0.02% invested in the company for 160,459 shares. Ameritas Invest Partners accumulated 228 shares or 0% of the stock. Fred Alger Management Incorporated has invested 0% of its portfolio in Theravance Biopharma Inc (NASDAQ:TBPH). Price T Rowe Assocs Md last reported 0% of its portfolio in the stock.
Insider Transactions: Since August 18, 2016, the stock had 0 insider purchases, and 3 selling transactions for $1.74 million net activity. On Thursday, August 25 the insider HAUMANN BRETT K sold $125,703. Shafer Bradford J sold 49,122 shares worth $1.35M.
More news for Theravance Biopharma Inc (NASDAQ:TBPH) were recently published by: Seekingalpha.com, which released: “Theravance Biopharma: The Sell-Side Is Struck With Blindness” on October 17, 2016. Seekingalpha.com‘s article titled: “Theravance Biopharma: Will The Outperformance Continue?” and published on August 10, 2016 is yet another important article.
TBPH Company Profile
Theravance Biopharma, Inc. (Theravance Biopharma) is a biopharmaceutical company. The Firm is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Firm operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. The Company’s commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease (COPD). The Company’s neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases, such as diabetic nephropathy. Neprilysin (NEP) is an enzyme that degrades natriuretic peptides.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.